-->

Spectral Med Stock Debt To Equity

EDT Stock  CAD 0.82  0.01  1.20%   
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Spectral Med's long-term financial health and intrinsic value.
Last ReportedProjected for Next Year
Debt To Equity(0.54)(0.51)
As of the 2nd of August 2025, Debt To Equity is likely to grow to -0.51.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Spectral Med Company Debt To Equity Analysis

Spectral Med's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

 = 

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current Spectral Med Debt To Equity

    
  16.30 %  
Most of Spectral Med's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Spectral Med is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Spectral Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Spectral Med is extremely important. It helps to project a fair market value of Spectral Stock properly, considering its historical fundamentals such as Debt To Equity. Since Spectral Med's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Spectral Med's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Spectral Med's interrelated accounts and indicators.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Competition

Spectral Total Stockholder Equity

Total Stockholder Equity

(26.17 Million)

Spectral Med reported last year Total Stockholder Equity of (27.55 Million)
According to the company disclosure, Spectral Med has a Debt To Equity of 16.3%. This is 69.56% lower than that of the Biotechnology sector and 79.0% lower than that of the Health Care industry. The debt to equity for all Canada stocks is 66.53% higher than that of the company.

Spectral Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Spectral Med's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Spectral Med could also be used in its relative valuation, which is a method of valuing Spectral Med by comparing valuation metrics of similar companies.
Spectral Med is currently under evaluation in debt to equity category among its peers.

Spectral Med Current Valuation Drivers

We derive many important indicators used in calculating different scores of Spectral Med from analyzing Spectral Med's financial statements. These drivers represent accounts that assess Spectral Med's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Spectral Med's important valuation drivers and their relationship over time.
202020212022202320242025 (projected)
Market Cap94.2M55.5M99.8M118.4M106.6M111.9M
Enterprise Value89.0M47.2M99.0M124.0M111.6M117.2M

Spectral Fundamentals

About Spectral Med Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Spectral Med's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Spectral Med using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Spectral Med based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Pair Trading with Spectral Med

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Spectral Med position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spectral Med will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Spectral Med could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Spectral Med when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Spectral Med - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Spectral Med to buy it.
The correlation of Spectral Med is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Spectral Med moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Spectral Med moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Spectral Med can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Spectral Stock

Spectral Med financial ratios help investors to determine whether Spectral Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Spectral with respect to the benefits of owning Spectral Med security.